AbbVie-backed Disco gets down with €20M to find new targets for antibody-based therapies

Disco Pharmaceuticals has arrived on the dance floor with the backing of AbbVie’s VC arm and €20 million ($21.8 million) in seed financing to cut a rug with its lung and colorectal cancer candidates.